12:00 AM
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Prurisol abacavir acetate: Completed Phase I enrollment

Cellceutix completed enrollment of about 18 healthy volunteers in a 2-part, open-label, crossover, U.S. Phase I bioequivalence trial to compare oral Prurisol vs. Ziagen abacavir sulfate. Subjects will receive single escalating-doses of 50, 100 and 200 mg Prurisol in the first part and...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >